MetaCap

Apnimed (APMD) vs Avalo Therapeutics (AVTX)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.

Summary

Apnimed is the larger company by market cap ($751.0 million vs $728.3 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

APMD-27.84%AVTX-25.59%
+33%+1%-31%
Jul 31, 20261 yearOct 7, 2026
APMD-27.84%AVTX-25.59%
+30%-0%-31%
Jul 27, 20265 yearsOct 5, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

APMD versus AVTX key metrics
MetricAPMDAVTX
Share price$18.04$13.58
Market cap$751.02M$728.30M
1-day change-3.27%-0.07%
YTD return—-25.22%
1-year return—+0.74%
5-year return—-99.79%
P/E ratio (TTM)2.50—
EPS (TTM)$7.22$-4.31
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
52-week high$35.29$24.27
52-week low$16.12$12.51
Distance from 52-week high-48.88%-44.05%
Average volume558.59K935.17K
Shares outstanding41.63M53.63M
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

APMD vs AVTX FAQ

Which is bigger, Apnimed or Avalo Therapeutics?

Apnimed (APMD) is larger, with a market capitalization of $751.02M compared with $728.30M for Avalo Therapeutics (AVTX).

Are Apnimed and Avalo Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons